Donor T cells for CAR T cell therapy.
CRISPR-Cas9
Donor CAR T cells
GVHD
Genome editing
TALENs
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
received:
13
12
2021
accepted:
26
02
2022
entrez:
2
4
2022
pubmed:
3
4
2022
medline:
3
4
2022
Statut:
epublish
Résumé
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR T cells is limited by prolonged lymphopenia in heavily pre-treated patients and risk of contamination with tumor cells when isolating T cells from patient blood rich in malignant blasts. Donor T cells provide a good source of immune cells for adoptive immunotherapy and can be used to generate universal off-the-shelf CAR T cells that are readily available for administration into patients as required. Genome editing tools such as TALENs and CRISPR-Cas9 and non-gene editing methods such as short hairpin RNA and blockade of protein expression are currently used to enhance CAR T cell safety and efficacy by abrogating non-specific toxicity in the form of graft versus host disease (GVHD) and preventing CAR T cell rejection by the host.
Identifiants
pubmed: 35365224
doi: 10.1186/s40364-022-00359-3
pii: 10.1186/s40364-022-00359-3
pmc: PMC8973942
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
14Subventions
Organisme : Inner Wheel Foundation
ID : Cord blood: a new cell source for T cell engineering
Organisme : Inner Wheel Foundation
ID : adoptive immunotherapy
Informations de copyright
© 2022. The Author(s).
Références
Hum Immunol. 2012 Feb;73(2):141-9
pubmed: 22154724
Mol Ther. 2016 Mar;24(3):570-81
pubmed: 26502778
Mol Ther. 2018 Aug 1;26(8):1883-1895
pubmed: 29861327
Lancet. 2020 Dec 12;396(10266):1885-1894
pubmed: 33308471
Mol Ther Methods Clin Dev. 2018 Dec 31;12:145-156
pubmed: 30666307
Nat Med. 2018 Oct;24(10):1499-1503
pubmed: 30275568
Mol Ther. 2017 Oct 4;25(10):2245-2253
pubmed: 28803861
Leukemia. 2021 Dec;35(12):3466-3481
pubmed: 34035409
Nat Med. 2017 Feb;23(2):242-249
pubmed: 28067900
Lancet. 2021 Jul 24;398(10297):314-324
pubmed: 34175021
Exp Hematol. 2013 Jan;41(1):39-55.e10
pubmed: 22999867
Blood. 2013 Dec 12;122(25):4129-39
pubmed: 24055823
Blood Adv. 2018 Mar 13;2(5):517-528
pubmed: 29507075
Onco Targets Ther. 2020 Nov 25;13:12163-12168
pubmed: 33268994
Nat Rev Drug Discov. 2020 Mar;19(3):185-199
pubmed: 31900462
J Clin Oncol. 2021 Oct 20;39(30):3340-3351
pubmed: 34324392
Nat Med. 2018 Jul;24(7):939-946
pubmed: 29892062
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Blood. 1997 May 15;89(10):3700-7
pubmed: 9160675
Mol Ther. 2017 Jan 4;25(1):285-295
pubmed: 28129122
Blood Cancer J. 2021 Apr 29;11(4):84
pubmed: 33927192
J Clin Oncol. 2020 Sep 20;38(27):3119-3128
pubmed: 32401634
Blood. 2020 Sep 17;136(12):1407-1418
pubmed: 32483603
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
J Clin Oncol. 2016 Apr 1;34(10):1112-21
pubmed: 26811520
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Blood. 2019 Aug 15;134(7):636-640
pubmed: 31648294
Blood. 2021 Jul 8;138(1):11-22
pubmed: 33827116
Mol Immunol. 2004 Apr;40(18):1295-305
pubmed: 15072848
Mol Ther. 2020 Aug 5;28(8):1783-1794
pubmed: 32485137
Am J Transplant. 2013 Jan;13(1):45-55
pubmed: 23016879
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):E2579-86
pubmed: 22949671
J Clin Med. 2019 Nov 14;8(11):
pubmed: 31739455
Leukemia. 2010 Jun;24(6):1160-70
pubmed: 20428207
J Cell Biol. 1996 Feb;132(3):299-310
pubmed: 8636209
Blood. 1997 Nov 1;90(9):3789-98
pubmed: 9345067
Blood. 2011 Nov 3;118(18):4817-28
pubmed: 21849486
Transfusion. 2018 Jan;58(1):88-99
pubmed: 29023759
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
Blood Cancer J. 2021 Jun 23;11(6):119
pubmed: 34162832
Mol Ther. 2017 Mar 1;25(3):580-592
pubmed: 28187946
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Sci Transl Med. 2017 Jan 25;9(374):
pubmed: 28123068
Curr Hematol Malig Rep. 2018 Oct;13(5):396-406
pubmed: 30120708
Blood Adv. 2021 Oct 26;5(20):4064-4072
pubmed: 34461630
Lancet. 2021 Aug 7;398(10299):491-502
pubmed: 34097852
Blood. 2017 Mar 2;129(9):1134-1142
pubmed: 28115371
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
Mol Ther. 2021 Feb 3;29(2):702-717
pubmed: 33129371
Mol Ther. 2014 Nov;22(11):1983-91
pubmed: 25048215
Nucleic Acids Res. 2013 Nov;41(21):9779-85
pubmed: 23980031
Blood. 2021 Jul 22;138(3):273-282
pubmed: 34292325
Immunotargets Ther. 2021 Apr 28;10:123-140
pubmed: 33954150
Mol Ther. 2016 Aug;24(7):1216-26
pubmed: 27138041
N Engl J Med. 2015 Oct 15;373(16):1541-52
pubmed: 26465987
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Nat Rev Mol Cell Biol. 2013 Jan;14(1):49-55
pubmed: 23169466
Cancer Immunol Res. 2020 Jul;8(7):926-936
pubmed: 32321775
Leukemia. 2020 Mar;34(3):909-913
pubmed: 31628429
Nat Rev Immunol. 2011 Apr;11(4):251-63
pubmed: 21394103
Mol Ther Methods Clin Dev. 2019 Nov 29;16:136-144
pubmed: 31988978
Expert Rev Hematol. 2012 Aug;5(4):409-25
pubmed: 22992235
Nature. 2019 Dec;576(7785):149-157
pubmed: 31634902
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10564-9
pubmed: 9724743
Immunology. 2002 May;106(1):27-37
pubmed: 11972629
Cancers (Basel). 2020 Jan 28;12(2):
pubmed: 32012891
Blood. 2013 Oct 24;122(17):2965-73
pubmed: 24030379
Nature. 2017 Nov 23;551(7681):464-471
pubmed: 29160308
Blood. 2009 Dec 10;114(25):5136-45
pubmed: 19828704
J Immunother Cancer. 2019 Aug 1;7(1):202
pubmed: 31370892
Clin Cancer Res. 2021 May 15;27(10):2764-2772
pubmed: 33627493
Hematology. 2010 Aug;15(4):230-5
pubmed: 20670482
Br J Haematol. 2004 Oct;127(2):140-54
pubmed: 15461619
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Leukemia. 2018 Nov;32(11):2307-2315
pubmed: 30315238
Front Immunol. 2021 Jan 08;11:618427
pubmed: 33488631
Science. 2011 Sep 30;333(6051):1843-6
pubmed: 21960622
Nature. 2016 Apr 20;533(7603):420-4
pubmed: 27096365
Mol Ther Oncolytics. 2018 Dec 20;12:124-137
pubmed: 30740516
Front Oncol. 2020 May 27;10:849
pubmed: 32670869
Immunol Rev. 2003 Feb;191:38-46
pubmed: 12614350
J Hematol Oncol. 2019 Dec 29;12(1):141
pubmed: 31884955
Oncoimmunology. 2017 Jan 19;6(3):e1283460
pubmed: 28405508
Int Immunol. 2013 Oct;25(10):601-11
pubmed: 23988616
Front Immunol. 2021 Oct 06;12:744823
pubmed: 34691052
Blood. 2021 Oct 21;138(16):1391-1405
pubmed: 33974080
Nature. 2018 Jul;559(7714):405-409
pubmed: 29995861
Breast Cancer Res. 2016 Jan 26;18(1):10
pubmed: 26810608
Science. 2012 Aug 17;337(6096):816-21
pubmed: 22745249
Nat Biotechnol. 2013 Sep;31(9):822-6
pubmed: 23792628
Blood. 2015 Dec 24;126(26):2882-91
pubmed: 26450984
Blood. 2012 Jun 14;119(24):5697-705
pubmed: 22535661
Blood. 2021 Oct 21;138(16):1504-1509
pubmed: 34010392
Curr Hematol Malig Rep. 2019 Aug;14(4):261-268
pubmed: 31243643
Blood. 2003 Apr 1;101(7):2693-703
pubmed: 12446444
Cancer Discov. 2013 Apr;3(4):388-98
pubmed: 23550147
J Hematol Oncol. 2017 Jan 31;10(1):35
pubmed: 28143567
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Immunity. 2006 Feb;24(2):133-9
pubmed: 16473826
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Leukemia. 2021 Jun;35(6):1563-1570
pubmed: 33077866
Immunotherapy. 2017 Jan;9(2):123-130
pubmed: 28128714
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
EMBO Mol Med. 2018 Nov;10(11):
pubmed: 30224381
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Cytotherapy. 2016 Aug;18(8):1002-1011
pubmed: 27378344